References
1. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis & Rheumatology . 2020/05/10 2020;n/a(n/a)doi:10.1002/art.41247
2. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis care & research . Oct 2012;64(10):1431-1446. doi:10.1002/acr.21772
3. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the rheumatic diseases . Jan 2017;76(1):29-42. doi:10.1136/annrheumdis-2016-209707
4. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology . Aug 2007;46(8):1372-4. doi:10.1093/rheumatology/kem056a
5. Khanna P, Hagerty D, Mischler R, Morlock R. FRI0397 Adherence to EULAR recommendations for the treatment of GOUT. Annals of the rheumatic diseases . 2014;71(Suppl 3):448-449. doi:10.1136/annrheumdis-2012-eular.2854
6. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis and rheumatism . Jun 15 2004;51(3):321-5. doi:10.1002/art.20405
7. Dalbeth N, House ME, Horne A, Taylor WJ. Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout. BMC musculoskeletal disorders . Dec 21 2013;14:363. doi:10.1186/1471-2474-14-363
8. Feig DI. Hyperuricemia and hypertension. Advances in chronic kidney disease . Nov 2012;19(6):377-385. doi:10.1053/j.ackd.2012.05.009
9. Kuwabara M, Hisatome I, Niwa K, et al. Uric Acid Is a Strong Risk Marker for Developing Hypertension From Prehypertension: A 5-Year Japanese Cohort Study. Hypertension . Jan 2018;71(1):78-86. doi:10.1161/HYPERTENSIONAHA.117.10370
10. Sluijs I, Beulens JW, van der AD, Spijkerman AM, Schulze MB, van der Schouw YT. Plasma uric acid is associated with increased risk of type 2 diabetes independent of diet and metabolic risk factors. The Journal of nutrition . Jan 2013;143(1):80-85. doi:10.3945/jn.112.167221
11. Chen LY, Zhu WH, Chen ZW, et al. Relationship between hyperuricemia and metabolic syndrome. Journal of Zhejiang University Science B . Aug 2007;8(8):593-8. doi:10.1631/jzus.2007.B0593
12. Mehmet Kanbay MS, Baris Afsar, et al. . The role of uric acid in the pathogenesis of human cardiovascular desease. Heart . 2013;99:759-756.
13. Jensen T, Niwa K, Hisatome I, et al. Increased Serum Uric Acid over five years is a Risk Factor for Developing Fatty Liver. Sci Rep . Aug 6 2018;8(1):11735. doi:10.1038/s41598-018-30267-2
14. Hande KR, Noone RM, Stone WJ. Severe Allopurinol Toxicity: Description and Guidelines for Prevention in Patients with Renal Insufficiency. The American journal of medicine . 1984;76:47-56.
15. Chung WH, Chang WC, Stocker SL, et al. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Annals of the rheumatic diseases . Dec 2015;74(12):2157-2164. doi:10.1136/annrheumdis-2014-205577
16. Yang CY, Chen CH, Deng ST, et al. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan. JAMA Intern Med . Sep 2015;175(9):1550-7. doi:10.1001/jamainternmed.2015.3536
17. Hung SL, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.P Natl Acad Sci USA . Mar 15 2005;102(11):4134-4139. doi:10.1073/pnas.0409500102
18. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol . Aug 2006;33(8):1646-50.
19. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis and rheumatism . Aug 2012;64(8):2529-36. doi:10.1002/art.34488
20. Wen CC, Yee SW, Liang X, et al. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther . May 2015;97(5):518-525. doi:10.1002/cpt.89
21. Roberts RL, Wallace MC, Phipps-Green AJ, et al. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J . Mar 2017;17(2):201-203. doi:10.1038/tpj.2015.101
22. Wallace MC, Roberts RL, Nanavati P, et al. Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis. Rheumatology . Apr 1 2018;57(4):656-660. doi:10.1093/rheumatology/kex467
23. Brackman DJ, Yee SW, Enogieru OJ, et al. Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol. Clin Pharmacol Ther . Sep 2019;106(3):623-631. doi:10.1002/cpt.1439
24. Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet . Jun 2009;5(6):e1000504.
25. Roman YM, Culhane-Pera K, Lo M, et al. The Impact of rs505802 forSLC22A12 on Oxipurinol and Uric Acid Disposition in Hmong Patients on Allopurinol from the Genetics of Hyperuricemia Therapy in Hmong (GOUT-H) Study. Clinical Pharmacology & Therapeutics . 2017;101(S1;PI-110):S5-S99. doi:10.1002/cpt.570
26. Stocker SL, McLachlan AJ, Savic RM, et al. The pharmacokinetics of oxypurinol in people with gout. British journal of clinical pharmacology . Sep 2012;74(3):477-89. doi:10.1111/j.1365-2125.2012.04207.x
27. Wright DF, Stamp LK, Merriman TR, Barclay ML, Duffull SB, Holford NH. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. Eur J Clin Pharmacol . Jul 2013;69(7):1411-21. doi:10.1007/s00228-013-1478-8
28. Graham GG, Kannangara DR, Stocker SL, et al. Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. British journal of clinical pharmacology . Dec 2013;76(6):932-8. doi:10.1111/bcp.12126
29. Wright DF, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK. Predicting allopurinol response in patients with gout. British journal of clinical pharmacology . Feb 2016;81(2):277-89. doi:10.1111/bcp.12799
30. Kannangara DRW, Graham GG, Wright DFB, et al. Individualising the dose of allopurinol in patients with gout. British journal of clinical pharmacology . Sep 2017;83(9):2015-2026. doi:10.1111/bcp.13307
31. Vora B, Brackman DJ, Zou L, et al. Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics. Clin Transl Sci . Jul 2021;14(4):1431-1443. doi:10.1111/cts.12992
32. Kottgen A, Albrecht E, Teumer A, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet . Feb 2013;45(2):145-154. doi:10.1038/ng.2500
33. Okada Y, Sim X, Go MJ, et al. Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. Nat Genet . Aug 2012;44(8):904-9. doi:10.1038/ng.2352
34. Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet . Apr 2008;40(4):437-42. doi:10.1038/ng.106
35. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed . Sep 2005;79(3):241-57. doi:10.1016/j.cmpb.2005.04.005
36. Lacroix BD, Friberg LE, Karlsson MO. Evaluation of IPPSE, an alternative method for sequential population PKPD analysis. J Pharmacokinet Pharmacodyn . Apr 2012;39(2):177-93. doi:10.1007/s10928-012-9240-x
37. Zhang L, Beal SL, Sheinerz LB. Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods. J Pharmacokinet Pharmacodyn . Dec 2003;30(6):405-16. doi:10.1023/b:jopa.0000012999.36063.4e
38. Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol . May 2011;38(5):904-910. doi:10.3899/jrheum.101160
39. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clinical pharmacokinetics . 2005;44(10):1051-65. doi:10.2165/00003088-200544100-00004
40. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels.Nature . May 23 2002;417(6887):447-52. doi:10.1038/nature742
41. Milionis HJ, Kakafika AI, Tsouli SG, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. American heart journal . Oct 2004;148(4):635-40. doi:10.1016/j.ahj.2004.04.005
42. Kose E, An T, Kikkawa A, Matsumoto Y, Hayashi H. Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients.Biol Pharm Bull . 2014;37(2):226-31. doi:10.1248/bpb.b13-00418
43. Choi HK, Soriano LC, Zhang Y, Rodriguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ . 2012;344:d8190. doi:10.1136/bmj.d8190
44. Keizer RJ, Karlsson MO, Hooker A. Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol . Jun 26 2013;2:e50. doi:10.1038/psp.2013.24
45. R: A Language and Environment for Statistical Computing . R Foundation for Statistical Computing; 2021.
46. Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.Lancet . Jan 10 2004;363(9403):157-63. doi:10.1016/S0140-6736(03)15268-3
47. Wright DF, Doogue MP, Barclay ML, et al. A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. Eur J Clin Pharmacol . Jan 2017;73(1):71-78. doi:10.1007/s00228-016-2133-y
48. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J . Sep 2009;11(3):558-69. doi:10.1208/s12248-009-9133-0
49. Turnheim K, Krivanek P, Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.British journal of clinical pharmacology . Oct 1999;48(4):501-9. doi:10.1046/j.1365-2125.1999.00041.x
50. Andres TM, McGrane T, McEvoy MD, Allen BFS. Geriatric Pharmacology: An Update. Anesthesiol Clin . Sep 2019;37(3):475-492. doi:10.1016/j.anclin.2019.04.007
51. Stamp LK, Barclay ML, O’Donnell JL, et al. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharmacol Ther . Sep 2011;90(3):392-8. doi:10.1038/clpt.2011.113
52. Stamp LK, Chapman PT, Barclay M, et al. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.Clin Transl Sci . Jan 2020;13(1):110-115. doi:10.1111/cts.12686
53. Stamp LK, Chapman PT, Barclay ML, et al. How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis research & therapy . Nov 16 2018;20(1):255. doi:10.1186/s13075-018-1755-0
54. McAdams DeMarco MA, Maynard JW, Baer AN, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. Arthritis and rheumatism . Jan 2012;64(1):121-9. doi:10.1002/art.33315
55. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med . Apr 13 1998;158(7):741-51. doi:10.1001/archinte.158.7.741
56. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med . Apr 11 2005;165(7):742-8. doi:10.1001/archinte.165.7.742
57. Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case-control study. Arthritis Rheumatol . Jan 2014;66(1):185-96. doi:10.1002/art.38203
58. Weinman EJ, Eknoyan G, Suki WN. The influence of the extracellular fluid volume on the tubular reabsorption of uric acid. J Clin Invest . Feb 1975;55(2):283-91. doi:10.1172/JCI107931
59. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pharmacol . Dec 2008;155(7):1066-75. doi:10.1038/bjp.2008.343
60. Jutabha P, Anzai N, Kitamura K, et al. Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. The Journal of biological chemistry . Nov 5 2010;285(45):35123-32. doi:10.1074/jbc.M110.121301
61. Stamp LK, Barclay ML, O’Donnell JL, et al. Furosemide increases plasma oxypurinol without lowering serum urate–a complex drug interaction: implications for clinical practice. Rheumatology . Sep 2012;51(9):1670-6. doi:10.1093/rheumatology/kes091
62. Iwanaga T, Kobayashi D, Hirayama M, Maeda T, Tamai I. Involvement of Uric Acid Transporter in Increased Renal Clearance of the Xanthine Oxidase Inhibitor Oxypurinol Induced by a Uricosuric Agent, Benzbromarone. Drug metabolism and disposition: the biological fate of chemicals . 2005;33(12):1791-1795.
63. Anzai N, Miyazaki H, Noshiro R, et al. The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C terminus. The Journal of biological chemistry . Oct 29 2004;279(44):45942-50. doi:10.1074/jbc.M406724200
64. Miyazaki H, Anzai N, Ekaratanawong S, et al. Modulation of renal apical organic anion transporter 4 function by two PDZ domain-containing proteins. Journal of the American Society of Nephrology : JASN . Dec 2005;16(12):3498-506. doi:10.1681/ASN.2005030306
65. Higashino T, Matsuo H, Sakiyama M, et al. Common variant of PDZ domain containing 1 (PDZK1) gene is associated with gout susceptibility: A replication study and meta-analysis in Japanese population. Drug Metab Pharmacokinet . Dec 2016;31(6):464-466. doi:10.1016/j.dmpk.2016.07.004
66. Li M, Li Q, Li CG, et al. Genetic polymorphisms in the PDZK1 gene and susceptibility to gout in male Han Chinese: a case-control study.International journal of clinical and experimental medicine . 2015;8(8):13911-8.
67. Portis AJ, Laliberte M, Tatman P, et al. High prevalence of gouty arthritis among the Hmong population in Minnesota. Arthritis care & research . Oct 2010;62(10):1386-1391. doi:10.1002/acr.20232
68. Roman YM, Lor K, Xiong T, Culhane-Pera K, Straka RJ. Gout prevalence in the Hmong: a prime example of health disparity and the role of community-based genetic research. Per Med . May 2021;18(3):311-327. doi:10.2217/pme-2020-0107